Effect of Two or Six Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled Trial

PLoS Neglected Tropical Diseases

Volumn 10, Issue 3, 2016, Pages

  Kamgno, Joseph ^a,b   Nguipdop Djomo, Patrick ^a,b,c   Gounoue, Raceline ^a,b,c   Téjiokem, Mathurin ^d   Kuesel, Annette C ^e  

^a Centre for Research on Filariasis and other Tropical Diseases (CRFilMT)   (Cameroon)

^b UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d CENTRE PASTEUR DU CAMEROUN   (Cameroon)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; IVERMECTIN; PLACEBO; ANTHELMINTIC AGENT;

ADAPTATION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPARENT LIFE THREATENING EVENT; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; EVALUATION AND FOLLOW UP; FEMALE; GEOMETRY; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION COST; HUMAN; LOIASIS; MALE; MIDDLE AGED; MYALGIA; OUTCOME ASSESSMENT; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT; ADOLESCENT; CAMEROON; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALBENDAZOLE; ANTHELMINTICS; CAMEROON; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOIASIS; MALE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84962361031     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004492     Document Type: Article

References (48)

1. Zoure HG, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS neglected tropical diseases. 2011;5(6):e1210. Epub 2011/07/09. doi: 10.1371/journal.pntd.000121021738809; PubMed Central PMCID: PMC3125145.
2. Boussinesq M, Loiasis. Annals of tropical medicine and parasitology. 2006;100(8):715–31. Epub 2007/01/18. doi: 10.1179/136485906X11219417227650.
3. Nutman TB, Miller KD, Mulligan M, Ottesen EA, Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations. The Journal of infectious diseases. 1986;154(1):10–8. Epub 1986/07/01. 3458832.
4. Andy JJ, Bishara FF, Soyinka OO, Odesanmi WO, Loasis as a possible trigger of African endomyocardial fibrosis: a case report from Nigeria. Acta tropica. 1981;38(2):179–86. Epub 1981/06/01. 6115557.
5. Lukiana T, Mandina M, Situakibanza NH, Mbula MM, Lepira BF, Odio WT, et al. A possible case of spontaneous Loa loa encephalopathy associated with a glomerulopathy. Filaria journal. 2006;5:6. Epub 2006/05/12. doi: 10.1186/1475-2883-5-616686951; PubMed Central PMCID: PMC1471781.
6. Takougang I, Meli J, Lamlenn S, Tatah PN, Ntep M, Loiasis—a neglected and under-estimated affliction: endemicity, morbidity and perceptions in eastern Cameroon. Annals of tropical medicine and parasitology. 2007;101(2):151–60. Epub 2007/02/24. doi: 10.1179/136485907X15451117316501.
7. Klion AD, Ottesen EA, Nutman TB, Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up. The Journal of infectious diseases. 1994;169(3):604–10. Epub 1994/03/01. 8158033.
8. ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use) (1996) Guideline for Good Clinical Practice, E6, R1, 1996. www.ich.org.
9. Carme B, Boulesteix J, Boutes H, Puruehnce MF, Five cases of encephalitis during treatment of loiasis with diethylcarbamazine. The American journal of tropical medicine and hygiene. 1991;44(6):684–90. Epub 1991/06/01. 1858969.
10. Stanley SL, Jr.Kell O, Ascending paralysis associated with diethylcarbamazine treatment of M. loa loa infection. Tropical doctor. 1982;12(1):16–9. Epub 1982/01/01. 6951321.
11. Gardon J, Mace JM, Cadot E, Ogil C, Godin C, Boussinesq M, Ivermectin-based control of onchocerciasis in northern Cameroon: individual factors influencing participation in community treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1996;90(3):218–22. Epub 1996/05/01. 8758054.
12. Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno J, Ngoumou P, Chippaux JP, Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis. The American journal of tropical medicine and hygiene. 1998;58(4):461–9. Epub 1998/05/09. 9574793.
13. Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux JP, Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria journal. 2003;2Suppl 1:S4. Epub 2004/02/21. doi: 10.1186/1475-2883-2-S1-S414975061; PubMed Central PMCID: PMC2147657.
14. Ducorps M, Gardon-Wendel N, Ranque S, Ndong W, Boussinesq M, Gardon J, et al. [Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin]. Bull Soc Pathol Exot. 1995;88(3):105–12. Epub 1995/01/01. 8555762.
15. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M, Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350(9070):18–22. Epub 1997/07/05. doi: 10.1016/S0140-6736(96)11094-19217715.
16. Twum-Danso NA, Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filaria journal. 2003;2Suppl 1:S7. Epub 2004/02/21. doi: 10.1186/1475-2883-2-S1-S714975064; PubMed Central PMCID: PMC2147656.
17. World Health Organization (2012) Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for implementation. World Health Organization. Available: http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf.
18. Mectizan Expert Committee and APOC Technical Consultative Committee (2004) Recommendations for the treatment of onchocerciasis with Mectizan in areas co-endemic for onchocerciasis and Loiasis.
19. World Health Organization (2012) Provisional strategy for interruption lymphatic filariasis transmission in loiasis-endemic countries. Report of the meeting on lymphatic filariasis, malaria and integrated vector management, Accra, Ghana, March 2012. http://www.who.int/iris/bitstream/10665/75139/3/WHO_HTM_NTD_PCT_2012.6_eng.pdf?ua=1.
20. World Health Organization (2012) Provisional strategy for interruption lymphatic filariasis transmission in loiasis-endemic countries. Report of the meeting on lymphatic filariasis, malaria and integrated vector management, Accra, Ghana, March 2012. http://www.who.int/iris/bitstream/10665/75139/3/WHO_HTM_NTD_PCT_2012.6_eng.pdf?ua=1.
21. World Health Organization (2013) Report of the sixth meeting of the WHO Strategic and Technical Advisory Group for Neglected Tropical Diseases.
22. Diawara L, Traore MO, Badji A, Bissan Y, Doumbia K, Goita SF, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS neglected tropical diseases. 2009;3(7):e497. Epub 2009/07/22. doi: 10.1371/journal.pntd.000049719621091; PubMed Central PMCID: PMC2710500.
23. Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS neglected tropical diseases. 2012;6(9):e1825. doi: 10.1371/journal.pntd.000182523029586; PubMed Central PMCID: PMC3441490.
24. Tekle AH, Elhassan E, Isiyaku S, Amazigo UV, Bush S, Noma M, et al. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. Parasites & vectors. 2012;5:28. Epub 2012/02/09. doi: 10.1186/1756-3305-5-2822313631; PubMed Central PMCID: PMC3296569.
25. African Programme for Onchocerciasis Control (APOC) (2014) Rerport of the 38th session of the technical consultative committee (TCC), March 2014. http://www.who.int/entity/apoc/about/structure/tcc/tcc38_final_report_130814.pdf?ua=1.
26. African Programme for Onchocerciasis Control (APOC) (2012) Final Communiqué, Eighteenth Session of the Joint Action Forum 11–13 December 2012. http://www.who.int/apoc/publications/recommendations/en/index.html.
27. Klion AD, Massougbodji A, Horton J, Ekoue S, Lanmasso T, Ahouissou NL, et al. Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. The Journal of infectious diseases. 1993;168(1):202–6. Epub 1993/07/01. 8515109.
28. Kamgno J, Boussinesq M, Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia. Parasite. 2002;9(1):59–63. Epub 2002/04/10. 11938697.
29. Tabi TE, Befidi-Mengue R, Nutman TB, Horton J, Folefack A, Pensia E, et al. Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen. The American journal of tropical medicine and hygiene. 2004;71(2):211–5. Epub 2004/08/13. 15306713.
30. Tsague-Dongmo L, Kamgno J, Pion SD, Moyou-Somo R, Boussinesq M, Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia. Annals of tropical medicine and parasitology. 2002;96(7):707–15. Epub 2003/01/23. doi: 10.1179/00034980212500193312537632.
31. Kamgno J, Pion SD, Mackenzie CD, Thylefors B, Boussinesq M, Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events. The American journal of tropical medicine and hygiene. 2009;81(6):1056–61. Epub 2009/12/10. doi: 10.4269/ajtmh.2009.09–035619996437.
32. Dayan AD, Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta tropica. 2003;86(2–3):141–59. 12745134.
33. Horton J, Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology. 2000;121Suppl:S113–32. 11386684.
34. Jagota SC, Albendazole, a broad-spectrum anthelmintic, in the treatment of intestinal nematode and cestode infection: a multicenter study in 480 patients. Clinical therapeutics. 1986;8(2):226–31. 3516398.
35. McLaughlin SI, Radday J, Michel MC, Addiss DG, Beach MJ, Lammie PJ, et al. Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000. The American journal of tropical medicine and hygiene. 2003;68(5):568–73. 12812348.
36. Njenga SM, Wamae CN, Njomo DW, Mwandawiro CS, Molyneux DH, Impact of two rounds of mass treatment with diethylcarbamazine plus albendazole on Wuchereria bancrofti infection and the sensitivity of immunochromatographic test in Malindi, Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008;102(10):1017–24. doi: 10.1016/j.trstmh.2008.04.03918550135.
37. Koehler P, The biochemical basis of anthelmintic action and resistance. Int J Parasitol Drugs Drug Resist. 2001;31:336.
38. Martin R, Modes of Action of Anthelmintic Drugs. The Veterinary Journal1997;154:11. 9265850
39. Mirfazaelian A, Rouini MR, Dadashzadeh S, Dose dependent pharmacokinetics of albendazole in human. Biopharm Drug Dispos. 2002;23(9):379–83. doi: 10.1002/bdd.32712469331.
40. Mirfazaelian A, Rouini MR, Dadashzadeh S, Time dependent pharmacokinetics of albendazole in human. Biopharm Drug Dispos. 2003;24(5):199–204. doi: 10.1002/bdd.35512784319.
41. Steiger U, Cotting J, Reichen J, Albendazole treatment of echinococcosis in humans: effects on microsomal metabolism and drug tolerance. Clin Pharmacol Ther. 1990;47(3):347–53. 2311336.
42. Mackenzie CD, Geary TG, Gerlach JA, Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients. Filaria journal. 2003;2Suppl 1:S5. Epub 2004/02/21. doi: 10.1186/1475-2883-2-S1-S514975062; PubMed Central PMCID: PMC2147659.
43. Dominguez-Vazquez A, Taylor HR, Greene BM, Ruvalcaba-Macias AM, Rivas-Alcala AR, Murphy RP, et al. Comparison of flubendazole and diethylcarbamazine in treatment of onchocerciasis. Lancet. 1983;1(8317):139–43. Epub 1983/01/22. 6130195.
44. Slatko BE, Taylor MJ, Foster JM, The Wolbachia endosymbiont as an anti-filarial nematode target. Symbiosis. 2010;51(1):55–65. Epub 2010/08/24. doi: 10.1007/s13199-010-0067-120730111; PubMed Central PMCID: PMC2918796.
45. Hoerauf A, Specht S, Buttner M, Pfarr K, Mand S, Fimmers R, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Medical microbiology and immunology. 2008;197(3):295–311. doi: 10.1007/s00430-007-0062-117999080; PubMed Central PMCID: PMC2668626.
46. Hoerauf A, Specht S, Marfo-Debrekyei Y, Buttner M, Debrah AY, Mand S, et al. Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus. Parasitology research. 2009;104(2):437–47. Epub 2008/10/14. doi: 10.1007/s00436-008-1217-818850111.
47. Turner JD, Tendongfor N, Esum M, Johnston KL, Langley RS, Ford L, et al. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial. PLoS neglected tropical diseases. 2010;4(4):e660. Epub 2010/04/21. doi: 10.1371/journal.pntd.000066020405054; PubMed Central PMCID: PMC2854122.
48. D'Ambrosio MV, Bakalar M, Bennuru S, Reber C, Skandarajah A, Nilsson L, et al. Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope. Sci Transl Med. 2015;7(286):286re4. doi: 10.1126/scitranslmed.aaa348025947164.